Aug 11, 2026 · 6 min
Premium pricing rattles On Holding as three stocks slide
On Holdings Tumbles, Hims & Hers Drops, Venture Global Falls
The episode shows how pricing decisions, strategic expansion, and unsold LNG cargoes can quickly reshape investor expectations.
- 1On Holding suffered a historic stock drop after premium pricing weakened quarterly sales and forced a lower annual outlook.
- 2Hims & Hers fell ahead of earnings as it prepared to enter the peptide market and adjusted its forecasts.
- 3Venture Global missed earnings after unsold liquefied natural gas cargoes weighed on results.
Don't miss
On Holding’s historic stock drop after premium pricing hurt quarterly sales and lowered its annual outlook.
The brief
Bloomberg’s Bailey Lipschultz, Paul Sweeney, and Matt Griffin examine three sharp stock moves, beginning with On Holding’s historic decline after premium pricing hurt quarterly sales.
On Holding maintained its premium pricing strategy, but weaker sales forced the company to lower its annual outlook—turning brand positioning into a market liability.
Hims & Hers also came under pressure ahead of earnings as it adjusted its forecast and prepared to enter the peptide market, adding strategic uncertainty to the stock.
Venture Global’s earnings miss had a more concrete explanation: unsold liquefied natural gas cargoes weighed on the company’s results.
Together, the moves show investors reassessing growth stories when pricing power, expansion plans, or demand execution fail to meet expectations.
What was said on this episode
6 statements · 2 positive · 3 negative · 1 neutral
On Holding’s premium pricing strategy is performing poorly.
“Not too well.”
Listen at 1:05
Consumers are shifting toward more discounted products.
“In a market where we're seeing consumers shifting towards some of the, the more discounted products”
Listen at 1:07
Hims & Hers reduced the lower end of its annual adjusted EBITDA forecast.
“the telehealth company reduced the lower end of its adjusted EBITDA forecast for the year”
Listen at 1:57
Peptides are highly popular among younger people.
“It's it's all the rage with kind of the youth generation”
Listen at 2:18
Venture Global’s stock has doubled year-to-date.
“stock still has doubled so far this year”
Listen at 2:58
Venture Global’s stock moves with oil and LNG prices.
“one of those companies that just moves where oil and LNG is trading”
Listen at 3:05
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Hims & Hers Health
Peptide Therapeutics MarketListen to the full episode and explore every guest, topic, and moment on PodLume.